Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,274.05 -131.61 (-0.34%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,117.62 -26.51 (-0.33%) Bitcoin USD
57,406.34 -3,947.13 (-6.43%) CMC Crypto 200
1,195.94 -143.12 (-10.68%)
electroCore, Inc. (ECOR)
| Previous close | 6.12 |
| Open | 6.35 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 6.35 - 6.35 |
| 52-week range | 3.83 - 8.08 |
| Volume | |
| Avg. volume | 9,942 |
| Market cap | 38.117M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.42 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.10 |
GlobeNewswireelectroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 8, 4:30 PM EDTDomestic: 877-407-8835International: located her
- GlobeNewswire
Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its most recent Truvaga Plus consumer study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, Truvaga Plus helped its users improve sleep, focus, stress, energy, and mood. 39 participants were instructed to use the Truvaga Plus product at home
- GlobeNewswire
electroCore Announces the Launch of Truvaga Plus® for General Wellness
ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024. Our first general wellness product, Truvaga 350, exceeded our expectations and Truvaga Plus will be an exciting addition to the Truvaga brand. Truvaga Plus is engineer
